EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients

Kiyoshi Okazuka, Takayuki Shimizu, Ryosuke Tawara, Masako Matsuo, Kayoko Ichihara, Koji Izutsu

Journal of Clinical and Experimental Hematopathology · 2025

DOI: 10.3960/jslrt.24078 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2025. Verfasst von Kiyoshi Okazuka und 5 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceutical Company Limited, Tokyo, Japan. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Brentuximab Vedotin, Hodgkin Disease. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBrentuximab VedotinHodgkin DiseaseAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultDoxorubicinJapanProduct Surveillance, PostmarketingVinblastineEast Asian People

Stichwörter der Autor:innen

Hodgkin diseaseantineoplastic agentsbrentuximab vedotinlymphomapostmarketing product surveillance

Substanzen

Brentuximab VedotinDoxorubicinVinblastine

Autor:innen und Institutionen

  • Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
  • Division of Hematology, Department of Medicine, National Hospital Organization Tokyo Medical Center, Tokyo, Japan.
  • ICON Clinical Research GK, Osaka, Japan.
  • Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.

Zitieren

APA

Okazuka, K., Shimizu, T., Tawara, R., Matsuo, M., Ichihara, K., & Izutsu, K. (2025). Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.24078

Vancouver

Okazuka K, Shimizu T, Tawara R, Matsuo M, Ichihara K, Izutsu K. Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients. Journal of Clinical and Experimental Hematopathology. 2025. doi:10.3960/jslrt.24078

BibTeX
@article{Okazuka2025,
  author = {Okazuka, Kiyoshi and Shimizu, Takayuki and Tawara, Ryosuke and Matsuo, Masako and Ichihara, Kayoko and Izutsu, Koji},
  title = {Postmarketing surveillance of brentuximab vedotin for previously untreated Hodgkin lymphoma in Japanese patients},
  journal = {Journal of Clinical and Experimental Hematopathology},
  year = {2025},
  doi = {10.3960/jslrt.24078}
}
Kostenlos starten →